SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

CLARIFICATION ON UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2026

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings ascribed to them in the 1Q2027 Results Announcement (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcement dated 8 November 2026 in relation to the unaudited condensed interim consolidated financial statements for the three months ended 30 September 2026 ("**1Q2027 Results Announcement**").

The Board wishes to provide the following clarifications to the 1Q2027 Results Announcement:

(i) In relation to Section F, Paragraph 1(d)(ii):

As at 30 September 2026, the Company had 492,597,856 outstanding warrants (30 September 2025: Nil), which were allotted and issued on 24 June 2026 pursuant to the renounceable non-underwritten rights cum warrants issue undertaken by the Company ("**Warrants**"). Each outstanding Warrant carries the right to subscribe for one new ordinary share in the capital of the Company ("**Share**") at an exercise price of S$0.050 per Share.

The total number of new Shares that may be issued upon the exercise of all outstanding warrants is 492,597,856 Shares, representing 28.57% of the Company's total number of issued Shares (excluding treasury shares and subsidiary holdings) as at 30 September 2026 (30 September 2025: Nil).

Save as disclosed above, the Company had no other outstanding convertibles, treasury shares and subsidiary holdings as at 30 September 2026 and 30 September 2025.

(ii) In relation to Section F, Paragraph 4:

For the three months financial period ended 30 September 2026, the computation of diluted loss per Share did not adjust for the effects of potential new Shares arising from the exercise of the outstanding Warrants as they are out-of-money, and thus, would have had an anti-dilutive effect on the loss per Share calculation. For the corresponding three months financial period ended 30 September 2025, the Company had no outstanding convertibles and accordingly, basic and diluted loss per Share were the same.

Save for the above clarifications, all other information contained in the 1Q2027 Results Announcement remains unchanged.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
13 November 2026

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.